Mumbai (Maharashtra) [India], October 30: Cancer patients worldwide may soon have a new ray of hope in their battle against the traumatic side effect of chemotherapy-induced alopecia (CIA). A groundbreaking study has revealed that QR 678 Neo® therapy is showing remarkable efficacy in the treatment of persistent chemotherapy-induced alopecia in both men and women who have undergone cytotoxic chemotherapy for breast and lung cancers.
Chemotherapy-induced alopecia is a distressing and often terrifying side effect of cancer treatment, robbing patients of their self-esteem and confidence and having a huge physiological impact related to hair loss. Despite numerous efforts to find an effective pharmacological therapy, none have been universally accepted—until now.
Advertisement
QR 678 Neo® offers a remarkable advancement in the field of hair regrowth, particularly for individuals undergoing chemotherapy. Normally hair grows after chemotherapy ,but this innovative therapy not only facilitates the regrowth of hair but does so at an accelerated pace, resulting in the development of high-quality, healthy hair in a safe way. With the advent of QR 678 Neo®, cancer patients worldwide now have a renewed sense of hope for a brighter and more confident future. This groundbreaking solution signifies a substantial stride in the continuous fight against the adverse effects of cancer treatment.
In a landmark study, 20 patients who had experienced grade I and II persistent alopecia due to chemotherapy were selected to evaluate the efficacy of QR 678 Neo® therapy. These patients, comprising 8 men with a history of lung cancer and 12 women with a history of breast cancer, were aged between 25 and 60.
Advertisement
The QR 678 Neo® therapy involved the local administration of a 1.5 mL solution into the scalp skin of patients over a course of 8 sessions, spaced 3 weeks apart. To assess the treatment's effectiveness, patients were subjected to standard global photography, video microscopic assessments, and self-assessment questionnaires at the baseline, 6-month, and 1-year marks.
The results of the study have been nothing short of extraordinary in all the assessment parameters QR 678 Neo® formulation was found to be significantly effective in 95 % of the patients. No patient has any severe adverse effects. After 6 months, patients exhibited a remarkable improvement in the global assessment score, with a mean score increase of 12.71 in hair count. This positive trend continued at the 1-year follow-up, demonstrating that QR 678 Neo® therapy offers lasting results.
Dr. Vaibhav Kumar, a leading expert in the field, commented, "The formulation of QR 678® and QR 678® Neo has demonstrated significant safety and efficacy in addressing chemotherapy-induced alopecia in both men and women. This groundbreaking therapy is not only effective but also offers long-lasting results, ensuring that cancer patients can regain their confidence and self-esteem. It's a game-changer in the fight against chemotherapy's side effects of hair loss."
Perhaps most encouragingly, the treatment showed a high level of safety and patient satisfaction. Patients reported significant slowing of hair loss (mean satisfaction score of 4.2) and overall hair growth (mean score of 3.8), with mean scores of 3.4 for hair appearance and growth.
Advertisement
Importantly, no severe adverse effects were reported by any of the patients, and the treatment was well-tolerated. The QR 678 Neo® therapy offers cancer patients a glimmer of hope on their journey, not only in fighting the disease but also in maintaining their self-esteem and confidence throughout the often-arduous process of chemotherapy.
Disclaimer: The above is a sponsored post, the views expressed are those of the sponsor/author and do not represent the stand and views of Outlook Editorial.
